

FIGURE 1

07/431533




FIGURE 2

07/431533




FIGURE 3

07/431533





FIGURE 4

07/431533



07/431533

FIGURE 5




FIGURE 6






FIGURE 7

07/431533




07/431533

FIGURE 8




07/431533

FIGURE 9.




07/431533

FIGURE 10



07/431533

FIGURE 11



07/431533

FIGURE 12




FIGURE 13

07/431533





FIGURE 14



07/431533

FIGURE 15




FIGURE 16


ASSAY PROCEDURE:

FIGURE 17

07/431533

CORRELATION BETWEEN U-TAA SPECIFIC IMMUNE COMPLEXES
AND CLINICAL COURSE IN MELANOMA PATIENTS

